

## Research Article

# Mechanism of Traditional Tibetan Medicine Grubthobrildkr Alleviated Gastric Ulcer Induced by Acute Systemic Hypoxia in Rats

Mei Yang,<sup>1</sup> Zhanting Yang,<sup>1,2</sup> Yongfang Li,<sup>1</sup> Shanshan Su,<sup>3</sup> Zhanqiang Li<sup>1,2</sup> and Dianxiang Lu<sup>1,2</sup>

<sup>1</sup>Medical College of Qinghai University, Xining 810001, China

<sup>2</sup>Research Center for High Altitude Medicine, Key Laboratory of Application and Foundation for High Altitude Medicine Research in Qinghai Province (Qinghai-Utah Joint Research Key Lab for High Altitude Medicine), Qinghai University, Xining 810001, China

<sup>3</sup>Xining Customs District, Key Laboratory of Food Safety Research in Qinghai Province, Xining 810003, China

Correspondence should be addressed to Zhanqiang Li; zhanqiang\_li@163.com and Dianxiang Lu; ludianxiang@qhu.edu.cn

Received 29 November 2021; Accepted 4 March 2022; Published 5 April 2022

Academic Editor: Taiyoun Rhim

Copyright © 2022 Mei Yang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**Objective.** This study was aimed at investigating the potential mechanism of Grubthobrildkr (GTB) on systemic hypoxia-induced gastric ulcers in rats and at detecting the chemical profile of GTB. **Methods.** Male Sprague-Dawley rats were separated into control, hypoxia, hypoxia+omeprazole, and hypoxia+GTBs (0.25, 0.5, and 1.0 g·kg<sup>-1</sup>·d<sup>-1</sup>) groups. Systemic hypoxia was created in a hypobaric chamber to simulate 5000 m high altitude by adjusting the inner pressure and oxygen content for 6 days. After that, the ulcer index, pH, and volume of gastric juice were assessed. The levels of endothelin-1 (ET-1), gastrin (GAS), motilin (MTL), phospholipase A<sub>2</sub> (PLA<sub>2</sub>), and prostaglandin E<sub>2</sub> (PGE<sub>2</sub>) were detected by ELISA. The expression level of hydrogen potassium ATPase (H<sup>+</sup>-K<sup>+</sup>-ATPase), cyclooxygenase-1 (COX-1), and cyclooxygenase-2 (COX-2) was tested by western blotting. Chemical profile of GTB was revealed by UHPLC-Q-exactive hybrid quadrupole-orbitrap mass (UHPLC-Q-Orbitrap MS). **Results.** GTB decreased the ulcer index in rats under hypoxia for six days, which was related to increased pH and volume of gastric juice, enhanced MTL and PGE<sub>2</sub> levels, and decreased ET-1 and PLA<sub>2</sub> levels of gastric mucosa. Furthermore, GTB decreased the level of H<sup>+</sup>-K<sup>+</sup>-ATPase and COX-2 while increased COX-1 levels in gastric mucosal tissue. 44 constituents were identified by UHPLC-Q-Orbitrap MS in GTB. **Conclusion.** GTB exerted a gastroprotective effect to alleviate gastric ulceration induced by acute systemic hypoxia in rats. The effect of GTB increasing the volume and pH of gastric juice in rats under acute systemic hypoxia could be regulated by gastrointestinal hormones, including MTL and ET-1. Mechanically, gastrointestinal protection of GTB was based on inhibition of the protons pumping H<sup>+</sup>-K<sup>+</sup>-ATPase and regulation of prostaglandin family in rats.

## 1. Introduction

Some symptoms of digestive system such as peptic ulcer were frequently found in mountaineers and altitude people [1]. Both gastric acid and mucosal ischemia were involved in the etiology of stress ulcers [2]. In general, a physiological balance was maintained between gastric acid secretion and gastric mucosal defense. Mucosal lesions and subsequent gastric ulcers appeared when the balance was disrupted.

The decrease in gastric mucosal protective mechanism can be induced by many factors, including hypoxia [3]. A decrease in gastric mucosal blood flow led to gastric ischemia by destroying the lining of the mucosa, which is closely related to systemic hypoxia. The secretion of gastric acid is regulated by various gastrointestinal hormones, such as gastrin (GAS), motilin (MTL), and endothelin (ET) [4]. These gastrointestinal hormones also influenced the level of intercellular Ca<sup>2+</sup> and eventually activated H<sup>+</sup>-K<sup>+</sup>-ATPase. An

inhibition of protons pumping  $H^+-K^+-ATPase$  as a means of preventing gastric ulcer has attracted considerable attention for several years [5].

Prostaglandins (PGs) were a family of lipid compounds derived from the arachidonic acid pathway and mediated several physiological functions, including the regulation of inflammation and gastrointestinal protection [6]. PGs were not only found to prevent the formation of ulcers but also improve the healing of the ulcer [7]. According to the reports, the secretion of gastric acid was regulated by PGs, which increased mucosal blood flow and promoted the healing of the mucosa. Enzymes involved in PG synthesis include  $PLA_2$ , which influences the production of arachidonic acid, COX-1, and COX-2. The restoration of  $PGE_2$  to normal levels can reduce gastric mucosa lesions [8, 9].

Traditional Tibetan medicine is commonly used in Qinghai and Tibetan folk medicine to treat several gastric problems [10]. Grubthobrildkr (GTB), a Tibetan traditional medicine formula, composed of seven medicine components, *Gypsum Calcitumrubrum*, *Calcite*, *Corydalis hendersonii* Hemsl, *Terminalia chebula* Retz (enucleation), *Radix aucklandiae*, *Faeces Trogopterori*, *Apis cerana Fabr*, and *Lagotis brevityb* Maxim at a ratio of 4:2.4:3.6:2.4:2:1:2.4, had been widely used in ethno-medicine for the clinical therapy of gastrointestinal diseases [11, 12].

In our previous study, we established a systemic hypoxia-induced gastric ulcer rat model by feeding rats in hypobaric chamber-stimulated altitude of 5000 m for 2, 4, 6, 8, and 10 days, respectively, and the severe gastric ulcer was found in the 6-day hypoxia group [13]. We also found the protective effect of GTB on systemic hypoxia-induced gastric ulcers in rat [14]. However, it remains to elucidate the mechanism of GTB on stress ulcer induced by systemic hypoxia. In this article, we focused on detecting the gastrointestinal protective mechanism of GTB in rats.

## 2. Experimental

**2.1. Medicine Material and Preparation.** GTB was purchased from Qinghai Provincial Tibetan Medical Hospital, the authority in the area on Tibetan medicine, with the batch number of Z20110562. According to the specification, the recommended dosage of GTB for adults was 3.0 g (total raw materials/day). In rat, equivalent dose was about 7 times the human dose. Based on clinical observation of the safety of this medicine, we chose 5, 10, and 20 times the human dose as lower ( $0.25\text{ g}\cdot\text{kg}^{-1}\cdot\text{d}^{-1}$ ), middle ( $0.5\text{ g}\cdot\text{kg}^{-1}\cdot\text{d}^{-1}$ ), and high dosage ( $1.0\text{ g}\cdot\text{kg}^{-1}\cdot\text{d}^{-1}$ ), respectively. Three doses of GTB were suspended in distilled water and administrated by oral gavage for 6 days in this study. Omeprazole (Zhejiang Bohua Chemical Co., Ltd. Batch No. 1410021) at a dosage of  $7\text{ mg}\cdot\text{kg}^{-1}\cdot\text{d}^{-1}$  was used as a positive control medicine. Omeprazole was similarly suspended in distilled water and was mixed vigorously before oral gavage administration.

**2.2. Animal.** The study was approved by the Institutional Animal Care and Use Committee of the Qinghai University in accordance with NIH guidelines for the care and use of




FIGURE 1: Effect of GTB on mean gross lesion index and inhibition rate of gastric mucosal ulcer in rat under acute systemic hypoxia for 6 days. The five groups including hypoxia (H), H+omeprazole, H+GTB 0.25 g/kg, H+GTB 0.5 g/kg, and H+GTB 1 g/kg were induced by systemic hypoxia (rats exposed to hypoxia in hypobaric chamber, equal to the parameter in altitude 5000 m) for 6 days. Each value represents the mean  $\pm$  S.D. value of eight animals. \* $P < 0.05$  vs. hypoxia group.

laboratory animals. Male Sprague-Dawley rats (220–240 g) were obtained from Gansu Traditional Chinese Medicine College, China (certificate of quality: SYXK (甘) 2011-0001). The rats were housed with a 12h light-dark cycle at  $25^{\circ}\text{C} \pm 2^{\circ}\text{C}$  and in a relative humidity of 50%–60%. The rats were fed *ad libitum* on a diet of standard pellets and water. All possible efforts were made to minimize suffering and reduce the number of rats used. No rat died during the experiment. Sprague-Dawley rats were randomly divided into control, hypoxia, hypoxia+omeprazole, and hypoxia+GTBs (0.25, 0.5, and  $1.0\text{ g}\cdot\text{kg}^{-1}\cdot\text{d}^{-1}$ ) groups, with each group comprising of 12 rats. The hypoxic groups were exposed in hypobaric chamber (Guizhou Fenglei Aviation Ordnance Co., Ltd. DYC-3000), equal to the parameter in altitude of 5000 m. The rats were deprived of food for 24h before research time point. Finally, the rats were sacrificed by bleeding from the abdominal aorta under urethane anesthesia ( $1.0\text{ g}\cdot\text{kg}^{-1}$ ).

**2.3. Measurement of pH, Volume of Gastric Juice, and Ulcer Index in Gastric Ulcer Tissue.** The gastric secretion from sacrificed rat was gathered. The gastric content was centrifuged at 3000 rpm for 20 min ( $4^{\circ}\text{C}$ ), the volume of the gastric juice appearing in the supernatant was determined, and the total acidity was tested by pH 211 meter (Mettler Toledo Company). For ulcer index measurement, the stomach of the rat in each group was immediately filled with 5 mL of




FIGURE 2: Effect of GTB on volume (a) and pH (b) of gastric juice in rat under acute systemic hypoxia for 6 days ( $\bar{X} \pm s$ ,  $n = 12$ ). Rats were exposed to hypoxia (in hypobaric chamber, equal to the parameter in altitude 5000 m), hypoxia (H)+omeprazole treatment (7 mg/kg/d), and hypoxia (H)+GTBs-treatment (0.25, 0.5, and 1.0 mg/kg/d) for 6 days. The volume and pH of the gastric juice were detected. Results are expressed as mean  $\pm$  S.D. # $P < 0.05$  as compared with the control group; \* $P < 0.05$  as compared with the hypoxia group.

10% phosphate-buffered formalin (pH 7.0) and submerged in the same solution for 30 min. To evaluate the extent of damage, the gastric sections were opened along the greater curvature and rinsed with normal saline to remove gastric content and blood clot. The degree of gastric mucosal damage was evaluated and rated for gross pathology according to the ulcer score scale described by Dekanski et al. [15] The criteria for assessing macroscopic damage were scored as follows: no ulcer (score = 0), ulcer  $< 1$  mm (score = 1),  $1 < \text{ulcer} < 2$  mm (score = 2),  $2 < \text{ulcer} < 3$  mm (score = 3), and  $3 < \text{ulcer} < 4$  mm (score = 4). The sum of the total score was divided by the number of rats to obtain mean ulcer index for each group. The inhibition percentage was calculated using the following formula:  $[(\text{UI untreated} - \text{UI treated}) / \text{UI untreated}] \times 100$ .

**2.4. Determination of ET-1, GAS, and MTL Level in Blood.** Enzyme-linked immunosorbent assay (ELISA) kits were utilized to measure serumal ET-1, GAS, and plasmic MTL level. The test was performed in accordance with reagent instructions. The kits were obtained from R&D Systems, USA.

**2.5. Determination of PLA<sub>2</sub> and PGE<sub>2</sub> Level in Blood and Gastric Mucosa.** ELISA kits were utilized to measure PLA<sub>2</sub> and PGE<sub>2</sub> level in blood and gastric mucosa. The test was performed in accordance with reagent instructions (R&D Systems, USA).

**2.6. Western Blotting Analysis.** The protein expression level of H<sup>+</sup>-K<sup>+</sup>-ATPase, COX-1, and COX-2 in gastric mucosal tissue was investigated by western blotting analysis. Each frozen stomach tissue was homogenized in RIPA buffer and centrifuged at 10,000 g for 15 min at 4°C. The protein concentration of the supernatant was measured using BCA

protein assay kit (Beyotime Institute of Biotechnology, Shanghai, China) with bovine serum albumin as the standard sample. The protein (50  $\mu\text{g}/\text{lane}$ ) was separated using SDS-PAGE and transferred to polyvinyl difluoride membrane (GE, Fairfield, CT, USA). The membrane was blocked with TBST containing 5% nonfat dry milk and incubated with anti-H<sup>+</sup>-K<sup>+</sup>-ATPase antibody (Abcam Biotechnology, USA, ab2866), anti-COX-1 antibody (Abcam Biotechnology, USA, ab133319), and anti-COX-2 antibody (Abcam Biotechnology, USA, ab52237) at a concentration of 1:2000 overnight at 4°C. The membrane was incubated with goat anti-mouse IgG (Abcam Biotechnology) and goat anti-rabbit IgG (Abcam Biotechnology) at a concentration of 1:5000 and subsequently visualized using an enhanced chemiluminescence (ECL) kit (Beyotime Biotechnology Company, Beijing, China). Equal lane loading was assessed using GAPDH.

**2.7. Analysis of GTB Aqueous Extract Using UHPLC-Q-Exactive Hybrid Quadrupole-Orbitrap Mass.** The GTB powder (0.01 g) from aqueous extract was dissolved in 80% methanol/distilled water (10 mL) with ultrasonic extraction at room temperature and centrifuged at 12,000 rpm for 10 min, respectively. After filtrated with 0.22  $\mu\text{m}$  filter membrane, the supernatant (1  $\mu\text{L}$ ) was loaded into the UHPLC-MS system. Chromatographic separation was performed using Dionex Ultimate 3000 UHPLC system (Thermo Fisher Scientific, San Jose, CA, USA). The separation was achieved with Thermo Scientific Hypersil GOLD aQ C18 Column (2.1 mm  $\times$  100 mm, 1.9  $\mu\text{m}$ ) at 40°C, and the flow rate was 0.4 mL/min. The mobile phase consisted of water containing acetonitrile (0.1%  $v/v$  formic acid) (A) and 0.1%  $v/v$  formic acid-H<sub>2</sub>O (B), which were applied in the gradient elution as follows: 5% A at 0-




FIGURE 3: Effect of GTB on gastrin (a), endothelin-1 (b), and motilin (c) level in blood in rat under systemic hypoxia for 6 days ( $\bar{X} \pm s$ ,  $n = 12$ ). Rats were exposed to hypoxia (in hypobaric chamber, equal to the parameter in altitude 5000 m), hypoxia (H)+omeprazole treatment (7 mg/kg/d), and hypoxia (H)+GTBs-treatment (0.25, 0.5, and 1.0 mg/kg/d) for 6 days. The level of gastrin, endothelin-1, and motilin in blood in rat was detected by enzyme-linked immunosorbent assay (ELISA). Results were expressed as mean  $\pm$  S.D. <sup>#</sup> $P < 0.05$  as compared with the control group; <sup>\*</sup> $P < 0.05$  as compared with the hypoxia group.

2 min, 5-95% A for 2-42 min, 95% A for 42-46.9 min, and 5% A for 47-50 min (the equilibration time was 3 min). A Q-exactive hybrid quadrupole-orbitrap mass spectrometer (Thermo Scientific, San Jose, CA, USA) included heat electrospray ionization (HESI) and was operated in both positive and negative ion modes to compete MS. The flow rate of sheath gas was 45 arbitrary units with the capillary temperature of 320°C. The auxiliary gas was set up to 15 arbitrary units at 350°C. In both positive and negative modes, the capillary voltage was set to +3.5 or -2.8 kV. The resolution of the full MS scan was 70,000 with the range of 80-1200 m/z. Samples were analyzed under 20, 30, and 40 normalized collision energy (NCE) in MS2 mode and resolution (17,500). Thermo Xcalibur 3.0 software (Thermo Scientific, San Jose, CA, USA) was used for collection and analysis of data.

2.8. *Statistical Analysis.* The results were expressed as means  $\pm$  S.D. Differences between means were analyzed by one-way analysis of variance followed by Dunnett's or Student-Newman-Keuls test. Differences were considered statistically significant at  $P \leq 0.05$ .

### 3. Results

3.1. *The Effect of GTB Treatment on Gastric Acidity, Ulcer Index, and Volume of Gastric Juice.* We found that the gastric mucosal ulcer induced by systemic hypoxia was alleviated by GTB administration. Meanwhile, ulcer index was significantly increased under systemic hypoxia. After administered by middle and high dosage of GTB and omeprazole, the ulcer index was significantly reduced (Figure 1). The volume of gastric juice was significantly reduced under systemic




FIGURE 4: Effect of GTB on phospholipase A<sub>2</sub> (PLA<sub>2</sub>) level in blood (a) and gastric mucosa (b) in rat under systemic hypoxia for 6 days ( $\bar{X} \pm s$ ,  $n = 12$ ). Rats were exposed to hypoxia (in hypobaric chamber, equal to the parameter in altitude 5000 m), hypoxia (H)+omeprazole treatment (7 mg/kg/d), and hypoxia (H)+GTBs-treatment (0.25, 0.5, and 1.0 mg/kg/d) for 6 days. The level of phospholipase A<sub>2</sub> (PLA<sub>2</sub>) in blood and gastric mucosa in rat was detected by enzyme-linked immunosorbent assay (ELISA). Results were expressed as mean  $\pm$  S.D. <sup>#</sup> $P < 0.05$  as compared with the control group; <sup>\*</sup> $P < 0.05$  as compared with the hypoxia group.




FIGURE 5: Effect of GTB on prostaglandin E<sub>2</sub> (PGE<sub>2</sub>) level in blood (a) and gastric mucosa (b) in rat under systemic hypoxia for 6 days ( $\bar{X} \pm s$ ,  $n = 12$ ). Rats were exposed to hypoxia (in hypobaric chamber, equal to the parameter in altitude 5000 m), hypoxia (H)+omeprazole treatment (7 mg/kg/d), and hypoxia (H)+GTB-treatment (0.25, 0.5, and 1.0 mg/kg/d) for 6 days. The level of PGE<sub>2</sub> in blood and gastric mucosa in rat was detected by enzyme-linked immunosorbent assay (ELISA). Results were expressed as mean  $\pm$  S.D. <sup>#</sup> $P < 0.05$  as compared with the control group; <sup>\*</sup> $P < 0.05$  as compared with the hypoxia group.

hypoxia and was significantly increased after GTB and omeprazole treatment. Compared with hypoxia group, gastric acidity was significantly reduced after treatment with middle and high dosages of GTB and omeprazole (Figure 2).

3.2. The Effect of GTB Treatment on Level of GAS, ET-1, and MTL. GAS level was not obviously different among omeprazole and experimental groups. The level of ET-1 which was increased under hypoxia was significantly decreased after

GTB and omeprazole treatment ( $P < 0.05$ ). The MTL level had no significant difference between the hypoxia and control groups but was significantly increased after treatment with GTB (Figure 3).

3.3. The Effect of GTB Treatment on PLA<sub>2</sub> and PGE<sub>2</sub> Level in Serum and Gastric Mucosal Tissue. The level of PLA<sub>2</sub> in serum and gastric mucosal tissue was significantly increased under systemic hypoxia and which was significantly






FIGURE 6: Effect of GTB on hydrogen potassium ATPase ( $H^+-K^+$ -ATPase) protein expression in gastric mucosal tissue detected by Western blotting. Rats were exposed to hypoxia (in hypobaric chamber, equal to the parameter in altitude 5000 m), hypoxia (H)+omeprazole treatment (7 mg/kg/d), and hypoxia (H)+GTBs-treatment (0.25, 0.5, and 1.0 mg/kg/d) for 6 days. GAPDH protein expression was used as a control. Relative expression levels of  $H^+-K^+$ -ATPase. Data were expressed as mean  $\pm$  S.D. of three identical experiments. <sup>#</sup> $P < 0.05$  as compared with the control group; <sup>\*</sup> $P < 0.05$  as compared with the hypoxia group.

decreased after GTB treatment ( $P < 0.05$ ) (Figure 4). We found that the level of  $PGE_2$  which was decreased in gastric mucosal tissue was increased in serum under systemic hypoxia. After treatment with GTB, the level of  $PGE_2$  in serum and gastric mucosal tissue was both significantly increased compared with the hypoxia group ( $P < 0.05$ ) (Figure 5).

**3.4. The Effect of GTB Treatment on  $H^+-K^+$ -ATPase Protein Expression in Gastric Mucosal Tissue.** The protein expression level of  $H^+-K^+$ -ATPase was significantly increased under systemic hypoxia. Compared with the hypoxia group, the protein expression level of  $H^+-K^+$ -ATPase was downregulated after treatment with middle and high dosage of GTB and omeprazole (Figure 6).

**3.5. The Effect of GTB Treatment on COX-1 and COX-2 Protein Expressions in Gastric Mucosal Tissue.** The COX-1 level was decreased significantly under systemic hypoxia. Middle and high dosages of GTB treatment upregulated




FIGURE 7: Effect of GTB on cyclooxygenase-1 (COX-1) protein expression in gastric mucosal tissue in rat detected by Western blotting. Rats were exposed to hypoxia (in hypobaric chamber, equal to the parameter in altitude 5000 m), hypoxia (H)+omeprazole treatment (7 mg/kg/d), and hypoxia (H)+GTBs-treatment (0.25, 0.5, and 1.0 mg/kg/d) for 6 days. GAPDH protein expression was used as a control. Relative expression levels of COX-1. Data are mean  $\pm$  S.D. of three identical experiments. <sup>#</sup> $P < 0.05$  as compared with the control group; <sup>\*</sup> $P < 0.05$  as compared with the hypoxia group.

COX-1 level in gastric *mucosal* tissue (Figure 7). The level of COX-2 was increased under systemic hypoxia which was downregulated by GTB administration (Figure 8).

**3.6. Identification of the Compounds in GTB Using UHPLC-Q-Exactive Hybrid Quadrupole-Orbitrap Mass.** The total spectrum of chemical components in GTB aqueous extract was analyzed from both positive and negative ion models. 44 chemical components were identified by UHPLC-Q-Orbitrap MS analysis (Figure 9). It showed the characters of all 44 chemical constituents including chromatographic retention times, accurate molecular mass, and/or MS/MS data listed in Table 1. Among these, the peaks of 10, 11, 12, 16, and 37 were identified as magnoflorine, boldine, phellodendrine, berberrubine, and dehydrocostus lactone, respectively, according to the data comparison with reference standards. Peak 10 was identified as magnoflorine with a protonated  $m/z$  342.16998 ( $[M+H]^+$ ,  $C_{20}H_{24}NO_4$ ). The MS/MS experiment yielded a  $[M-(CH_3)_2NH]^+$  ion at  $m/z$  297.11166 ( $C_{18}H_{17}O_4$ ) [16]. Peak 11 was protonated boldine  $m/z$  328.15433 ( $[M+H]^+$ ,  $C_{19}H_{22}NO_4$ ). The MS/




FIGURE 8: Effect of GTB on cyclooxygenase-2 (COX-2) protein expression in gastric mucosal tissue in rat detected by Western blotting. Rats were exposed to hypoxia (in hypobaric chamber, equal to the parameter in altitude 5000 m), hypoxia (H)+omeprazole treatment (7 mg/kg/d), and hypoxia (H)+GTBs-treatment (0.25, 0.5, and 1.0 mg/kg/d) for 6 days. GAPDH protein expression was used as a control. Relative expression levels of COX-2. Data are mean  $\pm$  S.D. of three identical experiments. # $P < 0.05$  as compared with the control group; \* $P < 0.05$  as compared with the hypoxia group.

MS experiment yielded a  $[M-NH_2CH_3]^+$  ion at  $m/z$  297.11176 ( $C_{18}H_{17}O_4$ ) [17]. Peak 12 was identified as phellodendrine with a protonated  $m/z$  342.16998 ( $M^+$ ,  $C_{20}H_{24}NO_4$ ). The MS/MS experiment yielded a  $[M-C_9H_{10}O_2-CH_3]^+$  ion at  $m/z$  177.07811 ( $C_{10}H_{11}NO_2$ ) [14]. Peak 16 was identified as berberrubine with protonated  $m/z$  332.10738 ( $[M+H]^+$ ,  $C_{19}H_{16}NO_4$ ) [15]. Peak 37 was tentatively identified as dehydrocostus lactone with protonated  $m/z$  231.13796 ( $[M+H]^+$ ,  $C_{15}H_{19}O_2$ ). The MS/MS experiment yielded a ion at  $m/z$  185.13225 ( $[M-CO-H_2O]^+$ ) [18]. Furthermore, other peaks were tentatively identified based on the chemical composition and MS/MS data and TCM database as well as previously published studies [16–18].

#### 4. Discussion

Acute gastric mucosal lesion was life-threatening at high altitude where gastric mucosal balance may be disrupted. It was found that blood flow to the gastric mucosa

decreased because of systemic hypoxia affecting the physiological balance between gastric acid secretion and gastric mucosal defense. Provided changes in the gastrointestinal tissue during hypoxia are explored, which should be intervened by medicines, especially by traditional medicines.

With a history going back approximately 2,500 years, Tibetan medicine is considered one of the world's oldest known traditional medicines [19]. Several traditional Tibetan medicines had been used to treat gastric diseases with obvious effect, and Grubthobriidkri is one of the classic Tibetan medicines to treat gastric problems. According to the reports, GTB attenuated acetic acid-induced gastric ulcer through reducing the expression of COX-2 and inflammatory reaction [20]. GTB also alleviated stress gastric ulcer induced by water immersion and pylorus ligation in rat [21]. Although GTB had been used for centuries as an effective and safe prescription for gastric disease treatment, its mechanism in the treatment of acute stress gastric ulcer under systemic hypoxia needs to be researched. In our previous study, we established systemic hypoxia-induced gastric ulcer rat model in 2, 4, 6, 8, and 10 days, respectively, and we observed that the severe gastric ulcer was in the 6-day hypoxia group [13]. The protective effect of GTB was also detected by hematoxylin and eosin staining and ultrastructural observation in systemic hypoxia-induced gastric ulcer rat model for 6 days [14]. In this article, we focused on detecting the gastrointestinal protective mechanism of GTB in rats.

The volume of gastric juice was significantly reduced, and total gastric acidity and ulcer index were significantly increased under systemic hypoxia in rat. The gastric ulcer index was reduced and pH of gastric juice and gastric secretion volume in rat were increased after GTB administration. GAS was from G cells of pyloric antrum for gastric acid secretion, and we found that GAS levels were not changed under systemic hypoxia for six days. MTL has been identified in the blood of dogs by means of radioimmunoassay [22], with function of stimulating pepsin output and enhancing activity of the stomach [23]. We found that MTL levels were not influenced by systemic hypoxia for six days in rats. ET-1 was one of the proinflammatory cytokines for the contraction of blood vessels, playing an important role in gastric ulcer formation. The increasing secretion of ET-1 results in the occurrence of hypoxia, acidosis, and ulcers. We found that ET-1 level was increased under hypoxia. GTB administration decreased ET-1 level and increased the level of MTL in the blood significantly compared with the hypoxia group but GAS level was not influenced. The results could be explained that the effects of GTB increasing pH of gastric juice and gastric secretion volume were mainly regulated by ET-1 and MTL levels. GAS, MTL, and ET-1 were all found to influence the level of intercellular  $Ca^{2+}$  and eventually activated  $H^+-K^+-ATPase$  [24].  $H^+-K^+-ATPase$  are responsible for secreting acid into the gastric lumen, which catalyzes the exchange of one  $H^+$  for one  $K^+$  at the expense of an ATP molecule [25]. We found that the  $H^+-K^+-ATPase$




FIGURE 9: UHPLC-Q-exactive hybrid quadrupole-orbitrap mass analysis chromatogram of aqueous extract of GTB. (a) Total ion chromatograms (TIC) chromatogram in positive electrospray ionization (ESI) mode. (b) TIC chromatogram in negative ESI mode. Peaks 1–44 represent stachydrine, adenine, guanine, cinnamic acid, isovanillin, esculetin, 7,8-dihydroxycoumarin, anisic aldehyde, paeonol, corydine, boldine, phellodendrine, 7-hydroxycoumarin, bicuculline, protopine, berberrubine, baicalin, dihydropalmatine, allocryptopine, berberine, dehydroglucine, dihydrosanguinarine, curcumol, micheliolide, diosmetin, andrographolide, isosteviol, carnosol, glabrolide, cafestol, quillaic acid, clareolide, 6-gingerol, piperine, atractylenolide II, isoalantolactone, dehydrocostus lactone, lindenol, abietic acid, deoxyandrographolide, steviol, kahweol, nonivamide, and alpha-linolenic acid.

level in gastric mucosal tissue was increased under systemic hypoxia. GTB reversed the increased protein expression of  $H^+K^+$ -ATPase in gastric mucosal tissue induced by systemic hypoxia.

Prostaglandins (PGs), targets for the prophylactic effect of probiotics in gastric ulcers [23], were participant in the ulcer healing process by decreasing acid secretion, stimulating the production of mucus, bicarbonate, and phospholipids [26]. Enzymes involved in PGs synthesis include  $PLA_2$ , which influenced the production of arachidonic acid, COX-1, and COX-2.  $PGE_2$  is a member of PGs, the restoration of which can reduce gastric mucosa lesions [8, 9]. GTB treatment reduced  $PLA_2$  level both in serum and in gastric tissue in rat under systemic hypoxia. Although the level of  $PGE_2$  in serum was increased in the six-day hypoxia group, GTB treatment increased  $PGE_2$  level both in the serum

and in gastric tissue. Based on the dual contribution of PGs to inflammation and mucosal defense, the increased  $PGE_2$  level after GTB administration could be deduced to play a protective role in ulcer lesions under systemic hypoxia.

COX-1 was a house-keeping enzyme that produces cytoprotective PGs, while COX-2 was an inducible form of the enzyme that produces inflammatory PGs. The protein expression of COX-1 was found to be reduced, but COX-2 was increased under acute systemic hypoxia. GTB treatment was found to increase the protein expression level of COX-1 and decrease that of COX-2 in gastric tissue in rat. 44 constituents in Grubthobrildkr were identified by UHPLC-Q-Orbitrap MS. To the best of our knowledge, we did not find articles which report the relationship between the 44 ingredients and the treatment of gastric ulcer.



TABLE 1: Compounds identified in aqueous extract of GTB by UHPLC-Q-exactive hybrid quadrupole-orbitrap mass analysis.

No.	$t_R$ (min)	Observed mass (Da)	MS ( $m/z$ )		Error (ppm)	MS/MS ( $m/z$ )	Molecular formula	Identification
			Calculated mass (Da)	$m/z$				
1	0.64	144.10191 [M+H] <sup>+</sup>	144.10175	103.13138, 84.08134, 98.09679, and 70.06587	-1.11	—	C <sub>7</sub> H <sub>13</sub> NO <sub>2</sub>	Stachydrine
2	0.73	136.06177 [M+H] <sup>+</sup>	136.06165	109.05100	-0.88	—	C <sub>5</sub> H <sub>5</sub> N <sub>5</sub>	Adenine
3	0.86	152.05669 [M+H] <sup>+</sup>	152.05661	110.03516, 135.02991, 128.04541, and 107.04948	-0.53	—	C <sub>5</sub> H <sub>5</sub> N <sub>5</sub> O	Guanine
4	2.5	149.05971 [M+H] <sup>+</sup>	149.05962	121.06486, 118.04142, 131.04907, and 103.05457	-0.60	—	C <sub>9</sub> H <sub>8</sub> O <sub>2</sub>	Cinnamic acid
5	3.82	153.05462 [M+H] <sup>+</sup>	153.05449	125.05972, 93.07038, 111.96861, and 129.97884	-0.85	—	C <sub>8</sub> H <sub>8</sub> O <sub>3</sub>	Isovanillin
6	4.39	179.03389 [M+H] <sup>+</sup>	179.03365	151.03896, 114.94835, 123.04412, and 133.02834	-1.34	—	C <sub>9</sub> H <sub>6</sub> O <sub>4</sub>	Esculetin
7	4.4	179.03389 [M+H] <sup>+</sup>	179.03365	123.04412, 117.03340	-1.34	—	C <sub>9</sub> H <sub>6</sub> O <sub>4</sub>	7,8-Dihydroxycoumarin
8	5.36	137.05971 [M+H] <sup>+</sup>	137.05962	109.06524	-0.66	—	C <sub>8</sub> H <sub>8</sub> O <sub>2</sub>	Antisic aldehyde
9	6.63	167.07027 [M+H] <sup>+</sup>	167.07007	125.05970, 121.10149, 84.96030, and 110.03656	-1.20	—	C <sub>9</sub> H <sub>10</sub> O <sub>3</sub>	Paenol
10	7.26	342.16998 [M+H] <sup>+</sup>	342.16922	297.11166, 265.08533, and 237.09053	-2.22	—	C <sub>20</sub> H <sub>23</sub> NO <sub>4</sub>	Magnoflorine
11	7.92	328.15433 [M+H] <sup>+</sup>	328.15372	237.09117, 297.11176, 178.08595, and 163.06247	-1.86	—	C <sub>19</sub> H <sub>21</sub> NO <sub>4</sub>	Boldine
12	8.28	342.16998 M <sup>+</sup>	342.16934	192.10162, 177.07811	-1.87	—	C <sub>20</sub> H <sub>24</sub> NO <sub>4</sub>	Phellodendrine
13	8.84	163.03897 [M+H] <sup>+</sup>	163.03870	107.04945	-1.66	—	C <sub>9</sub> H <sub>6</sub> O <sub>3</sub>	7-Hydroxycoumarin
14	9.15	368.11218 [M+H] <sup>+</sup>	368.11218	307.05954, 277.04910, 249.05411, and 190.08597	-1.85	—	C <sub>20</sub> H <sub>17</sub> NO <sub>6</sub>	(+)-Bicuculline
15	9.73	354.13360 [M+H] <sup>+</sup>	354.13281	188.07033, 275.06979, 188.07033, and 149.05962	-2.23	—	C <sub>20</sub> H <sub>19</sub> NO <sub>5</sub>	Protopine
16	9.86	322.10738 [M+H] <sup>+</sup>	322.10690	279.08868, 234.09065, 307.08350, and 250.08571	-1.49	—	C <sub>19</sub> H <sub>15</sub> NO <sub>4</sub>	Berberrubine
17	9.95	447.09219 [M+H] <sup>+</sup>	447.09177	—	-0.94	—	C <sub>21</sub> H <sub>18</sub> O <sub>11</sub>	Baicalin
18	10.39	354.16998 [M+H] <sup>+</sup>	354.13232	336.12201, 320.09183, 190.08597, and 275.06976	-106.33	—	C <sub>21</sub> H <sub>23</sub> NO <sub>4</sub>	Dihydroalpmatine
19	10.60	370.16490 [M+H] <sup>+</sup>	370.16428	290.09338, 188.07036	-1.67	—	C <sub>21</sub> H <sub>23</sub> NO <sub>5</sub>	Allocriptopine
20	10.96	336.12303 M <sup>+</sup>	336.12247	278.08099, 292.09616	-1.67	—	C <sub>20</sub> H <sub>18</sub> NO <sub>4</sub>	Berberine
21	11.17	354.16998 [M+H] <sup>+</sup>	354.16943	338.13928, 306.12180, 192.10165, and 165.09084	-1.55	—	C <sub>21</sub> H <sub>23</sub> NO <sub>4</sub>	Dehydroglauicine
22	12.22	334.10738 [M+H] <sup>+</sup>	334.10669	319.08340, 261.07614, 302.07990, and 290.08054	-2.07	—	C <sub>20</sub> H <sub>15</sub> NO <sub>4</sub>	Dihydrosanguinarine
23	12.78	237.18491 [M+H] <sup>+</sup>	237.18472	196.01671, 182.98506	-0.80	—	C <sub>15</sub> H <sub>24</sub> O <sub>2</sub>	Curcuminol
24	14.00	249.14852 [M+H] <sup>+</sup>	249.14781	231.13780, 185.13234, 135.08034, and 119.08567	-2.85	—	C <sub>15</sub> H <sub>20</sub> O <sub>3</sub>	Micheliolide
25	14.24	301.07066 [M+H] <sup>+</sup>	301.07016	286.04666, 147.11650, 258.05185, and 229.04871	-1.66	—	C <sub>16</sub> H <sub>12</sub> O <sub>6</sub>	Diosmetin
26	14.72	351.21166 [M+H] <sup>-</sup>	351.21790	333.20121, 305.21259, 289.21765, and 183.10057	3.70	—	C <sub>20</sub> H <sub>30</sub> O <sub>5</sub>	Andrographolide
27	15.52	319.22677 [M+H] <sup>+</sup>	319.22577	273.22053, 255.21010, 301.21591, and 147.11681	-3.13	—	C <sub>20</sub> H <sub>30</sub> O <sub>3</sub>	Isosteviol
28	16.00	331.19039 [M+H] <sup>+</sup>	331.18976	285.18408, 215.10663, 203.10638, and 171.08023	-1.90	—	C <sub>20</sub> H <sub>26</sub> O <sub>4</sub>	Carnosol
29	16.12	469.33075 [M+H] <sup>+</sup>	469.33124	95.08595, 299.20111, 119.08565, and 405.31430	1.04	—	C <sub>30</sub> H <sub>44</sub> O <sub>4</sub>	Glabrolide
30	16.14	317.21112 [M+H] <sup>+</sup>	317.21118	281.19016, 131.08543, 299.20016, and 271.20538	0.19	—	C <sub>20</sub> H <sub>28</sub> O <sub>3</sub>	Cafestol
31	16.16	487.34024 [M+H] <sup>+</sup>	487.34180	451.32074, 187.14790, 119.08562, and 201.16367	3.20	—	C <sub>30</sub> H <sub>46</sub> O <sub>5</sub>	Quillaic acid
32	16.66	251.20056 [M+H] <sup>+</sup>	251.20020	1187.14793, 215.17897, 233.18958, and 95.08595	-1.43	—	C <sub>16</sub> H <sub>26</sub> O <sub>2</sub>	Clareolide
33	18.00	293.17583 [M+H] <sup>-</sup>	293.17603	236.10522, 177.09090, 221.15428, and 249.18590	0.68	—	C <sub>17</sub> H <sub>26</sub> O <sub>4</sub>	6-Gingerol
34	19.08	286.14377 [M+H] <sup>+</sup>	286.14334	201.05440, 143.04912, 135.04396, and 115.05444	-1.50	—	C <sub>17</sub> H <sub>19</sub> NO <sub>3</sub>	Piperine
35	20.38	233.15361 [M+H] <sup>+</sup>	233.15335	187.14793, 145.10107	-1.12	—	C <sub>15</sub> H <sub>20</sub> O <sub>2</sub>	Attractylenolide II

TABLE I: Continued.

No.	$t_R$ (min)	MS ( $m/z$ )		Error (ppm)	MS/MS ( $m/z$ )	Molecular formula	Identification
		Observed mass (Da)	Calculated mass (Da)				
36	20.28	233.15361 [M+H] <sup>+</sup>	233.15334	-1.16	187.14796, 159.11668, 215.14293, and 145.10109	C <sub>15</sub> H <sub>20</sub> O <sub>2</sub>	Isoalantolactone
37	20.84	231.13796 [M+H] <sup>+</sup>	231.13757	-1.69	185.13225, 143.08539, 195.11664, and 157.10092	C <sub>15</sub> H <sub>18</sub> O <sub>2</sub>	Dehydrocostus lactone
38	20.84	231.13796 [M+H] <sup>+</sup>	231.13757	-1.69	105.07019, 98.03719, 119.08562, and 131.08542	C <sub>15</sub> H <sub>18</sub> O <sub>2</sub>	Lindenerol
39	21.08	303.23186 [M+H] <sup>+</sup>	303.23138	-1.58	257.22589, 123.12687, and 147.11668	C <sub>20</sub> H <sub>30</sub> O <sub>2</sub>	Abietic acid
40	21.22	335.22169 [M+H] <sup>+</sup>	335.22305	4.06	289.21722, 129.90915, and 275.20213	C <sub>20</sub> H <sub>30</sub> O <sub>4</sub>	Deoxyandrographolide
41	21.27	319.22677 [M+H] <sup>+</sup>	319.22650	-0.85	227.14243, 273.22098, 255.21030, and 161.13228	C <sub>20</sub> H <sub>30</sub> O <sub>3</sub>	Steviol
42	22.42	315.19547 [M+H] <sup>+</sup>	315.19513	-1.08	303.97168, 145.06465, 187.11153, and 269.18951	C <sub>20</sub> H <sub>26</sub> O <sub>3</sub>	Kahweol
43	23.26	294.20637 [M+H] <sup>+</sup>	294.20685	1.63	161.09586, 137.05959, 179.10640, and 203.10635	C <sub>17</sub> H <sub>27</sub> NO <sub>3</sub>	Nonivamide
44	29.25	279.23186 [M+H] <sup>+</sup>	279.23145	-1.47	95.08595, 81.07049, and 67.05501	C <sub>18</sub> H <sub>30</sub> O <sub>2</sub>	Alpha-linolenic acid

 $t_R$ : retention time.

## 5. Conclusion

Traditional Tibetan patent medicine Grubthobrildkr showed a protective effect and alleviated the ulceration in gastric mucosa under systemic hypoxia. The effect of GTB increasing volume and pH of gastric juice in rat under acute systemic hypoxia could be regulated by MTL and ET-1. The molecular mechanism of GTB might be related to reduction of H<sup>+</sup>-K<sup>+</sup>-ATPase protein expression and regulation of prostaglandin family by downregulating COX-2 expression and upregulating COX-1 protein expression in the gastric mucosa of rats under systemic hypoxia. 44 constituents in GTB were identified by UHPLC-Q-TOF-MS/MS. Furthermore, comprehensive studies are needed to elucidate the gastroprotective mechanism of GTB.

## Glossary

GTB:	Grubthobrildkr
ET-1:	Endothelin-1
GAS:	Gastrin
PLA <sub>2</sub> :	Phospholipase A <sub>2</sub>
PGE <sub>2</sub> :	Prostaglandin E <sub>2</sub>
H <sup>+</sup> -K <sup>+</sup> -ATPase:	Hydrogen potassium ATPase
COX-1:	Cyclooxygenase-1
COX-2:	Cyclooxygenase-2
UHPLC-Q-Orbitrap MS:	UHPLC-Q-exactive hybrid quadrupole-orbitrap mass.

## Data Availability

The data used to support the findings of this study are included within the article.

## Additional Points

*Article Info.* Chemical compounds studied in this article: magnoflorine (Pubchem CID: 73337), boldine (Pubchem CID: 10154), phellodendrine (Pubchem CID: 59819), berberrubine (Pubchem CID: 72703), and dehydrocostus lactone (Pubchem CID: 73174).

## Ethical Approval

The study was approved by the Institutional Animal Care and Use Committee of Qinghai University in accordance with NIH guidelines for the care and use of laboratory animals.

## Conflicts of Interest

We declare that we have no conflict of interest.

## Authors' Contributions

Mei Yang and Zhanting Yang contributed equally to the work and should be considered co-first authors.

## Acknowledgments

This work was financed by grants from the National Natural Sciences Foundation of China (No. 81360687), Chunhui Program Foundation of Ministry of Education of China (No. Z2012083), Applied Basic Research Project of Qinghai Province of China (2021-ZJ-907), and West Light Foundation of the Chinese Academy of Sciences. The authors wish to thank Jin Guoen, Yang Quanyu, and Ga Qin for helping to operate the hypobaric chamber in this study.

## References

- [1] T. Y. Wu, S. Q. Ding, J. L. Liu et al., "High-altitude gastrointestinal bleeding: an observation in Qinghai-Tibetan railroad construction workers on Mountain Tanggula," *World Journal of Gastroenterology*, vol. 13, no. 5, pp. 774–780, 2007.
- [2] P. E. Marik, T. Vasu, A. Hirani, and M. Pachinburavan, "Stress ulcer prophylaxis in the new millennium: a systematic review and meta-analysis," *Critical Care Medicine*, vol. 38, no. 11, pp. 2222–2228, 2010.
- [3] A. F. Syam, M. Simadibrata, S. I. Wanandi, B. S. Hernowo, M. Sadikin, and A. A. Rani, "Gastric ulcers induced by systemic hypoxia," *Acta Medica Indonesiana*, vol. 43, no. 4, pp. 243–248, 2011.
- [4] T. Michida, S. Kawano, E. Masuda et al., "Endothelin-1 in the gastric mucosa in stress ulcers of critically ill patients," *The American Journal of Gastroenterology*, vol. 92, no. 7, pp. 1177–1181, 1997.
- [5] L. Lundell, "The physiological background behind and course of development of the first proton pump inhibitor," *Scandinavian Journal of Gastroenterology*, vol. 50, no. 6, pp. 680–684, 2015.
- [6] A. R. Ribeiro, P. B. Diniz, M. S. Pinheiro, R. L. Albuquerque-Júnior, and S. M. Thomazzi, "Gastroprotective effects of thymol on acute and chronic ulcers in rats: the role of prostaglandins, ATP-sensitive K(+) channels, and gastric mucus secretion," *Chemico-Biological Interactions*, vol. 25, no. 244, pp. 121–128, 2016.
- [7] S. Harada, T. Takeuchi, S. Edogawa, K. Ota, Y. Kojima, and K. Higuchi, "The availability of prostaglandin derivatives in a treatment and prevention for gastrointestinal mucosal injury," *Nihon Rinsho*, vol. 73, no. 7, pp. 1153–1158, 2015.
- [8] A. Tanaka, R. Hatazawa, Y. Takahira, N. Izumi, L. Filaretova, and K. Takeuchi, "Preconditioning stress prevents cold restraint stress-induced gastric lesions in rats: roles of COX-1, COX-2, and PLA<sub>2</sub>," *Digestive Diseases and Sciences*, vol. 52, no. 2, pp. 478–487, 2007.
- [9] S. Yamamoto, S. Ohki, N. Ogino et al., "Enzymes involved in the formation and further transformations of prostaglandin endoperoxides," *Advances in Prostaglandin and Thromboxane Research*, vol. 6, pp. 27–34, 1980.
- [10] R. Meier, P. Hengstler, F. Weber, H. Maurer, C. Bommeli, and R. Brignoli, "The Tibetan herbal formula Padma Digestin in functional dyspepsia: an open-label study," *Forschende Komplementärmedizin*, vol. 20, no. s2, pp. 2–7, 2013.
- [11] Y. P. Chen, S. Y. Wang, H. Y. Lu, C. J. Chen, and X. J. Li, "Clinical observation of Tibetan medicine Grubthobrildkr in peptic ulcer," *J. Qiqihai. Univer. Med.*, vol. 30, no. 5, pp. 555–556, 2008.

- [12] Y. Wang, Z. Song, and Y. P. Chen, "Clinical observation of Tibetan medicine Grubthobrildkr on peptic ulcer," *Chin. J. Trauma. Disability*, vol. 18, no. 2, pp. 77-78, 2010.
- [13] Y. LI and M. Yang, "Establishment of rat model of plateau hypoxia caused stress ulcer," *Chongqing Medicine*, vol. 46, no. 27, pp. 3825-3827, 2017.
- [14] M. Yang, L. Z. Deng, Z. Q. Li, Y. F. Li, and D. X. Lu, "The changes of gastrin and motilin in exposed to hypobaric hypoxia and the effect of Tibetan medicine in rats," *Journal of Qinghai Medical College*, vol. 29, no. 4, pp. 256-259, 2008.
- [15] D. Dekanski, S. Janićijević-Hudomal, S. Ristić et al., "Attenuation of cold restraint stress-induced gastric lesions by an olive leaf extract," *General Physiology and Biophysics*, vol. 28 Spec No, pp. 135-142, 2009.
- [16] Y. Chen, Z. Zhang, Y. Zhang et al., "A new method for simultaneous determination of phenolic acids, alkaloids and limonoids in *Phellodendri Amurensis Cortex*," *Molecules*, vol. 24, no. 4, p. 709, 2019.
- [17] Y. J. Wu, Y. L. Zheng, L. J. Luan et al., "Development of the fingerprint for the quality of *Radix Linderae* through ultra-pressure liquid chromatography-photodiode array detection/electrospray ionization mass spectrometry," *Journal of Separation Science*, vol. 33, no. 17-18, pp. 2734-2742, 2010.
- [18] Y. He, P. Cheng, W. Wang et al., "Rapid investigation and screening of bioactive components in simo decoction via LC-Q-TOF-MS and UF-HPLC-MD methods," *Molecules*, vol. 23, no. 7, p. 1792, 2018.
- [19] P. Roberti di Sarsina, L. Ottaviani, and J. Mella, "Tibetan medicine: a unique heritage of person-centered medicine," *The EPMA Journal*, vol. 2, no. 4, pp. 385-389, 2011.
- [20] Y. Zhao, C. Luo, X. M. Lan, Y. Liu, and Y. Z. Sun, "Mechanism of Zhituo Jiebai pills on gastric ulcer induced by acetic acid in mice," *J. JiangXi. Univ. TCM*, vol. 28, no. 3, p. 65-67+72, 2016.
- [21] Y. Liu, X. M. Lan, C. Luo, and Y. Zhao, "Study on the effect of Zhituo Jiebai pill on gastric ulcer in rats," *Lishizhen Med. Mater. Med. Res*, vol. 27, no. 1, pp. 82-84, 2016.
- [22] Z. Itoh, S. Takeuchi, I. Aizawa et al., "Changes in plasma motilin concentration and gastrointestinal contractile activity in conscious dogs," *Journal of Digestive Diseases*, vol. 23, no. 10, pp. 929-935, 1978.
- [23] G. Khoder, A. A. Al-Menhali, F. Al-Yassir, and S. M. Karam, "Potential role of probiotics in the management of gastric ulcer," *Experimental and Therapeutic Medicine*, vol. 12, no. 1, pp. 3-17, 2016.
- [24] M. L. Schubert, "Gastric secretion," *Current Opinion in Gastroenterology*, vol. 30, no. 6, pp. 578-582, 2014.
- [25] C. S. Chung, T. H. Chiang, and Y. C. Lee, "A systematic approach for the diagnosis and treatment of idiopathic peptic ulcers," *The Korean Journal of Internal Medicine*, vol. 30, no. 5, pp. 559-570, 2015.
- [26] R. Hatazawa, R. Ohno, M. Tanigami, A. Tanaka, and K. Takeuchi, "Roles of endogenous prostaglandins and cyclooxygenase isoenzymes in mucosal defense of inflamed rat stomach," *Journal of Pharmacology and Experimental Therapeutics*, vol. 55, pp. 193-205, 2004.